Ignite Creation Date:
2025-12-25 @ 3:31 AM
Ignite Modification Date:
2026-03-05 @ 2:07 PM
Study NCT ID:
NCT00548405
Status:
COMPLETED
Last Update Posted:
2017-04-17
First Post:
2007-10-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Sponsor:
Genzyme, a Sanofi Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-10
Start Date Type:
None
Primary Completion Date:
2011-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-09
Completion Date Type:
ACTUAL
First Submit Date:
2007-10-22
First Submit QC Date:
None
Study First Post Date:
2007-10-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-11-17
Results First Submit QC Date:
None
Results First Post Date:
2015-01-08
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2012-12-04
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2017-03-17
Last Update Post Date:
2017-04-17
Last Update Post Date Type:
ACTUAL